The short answer
The added bleeding risk from vitamin E supplements with ticagrelor is uncertain. Review the exact product, dose and your bleeding history with your prescriber.
What this answer covers
Oral vitamin E supplements with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable.
- Supplement or preparation
- Vitamin E
- Medication ingredient
- ticagrelor
What the evidence shows
NIH guidance notes that large supplemental vitamin E doses may affect clotting and platelet function. This supports a precaution with medicines affecting bleeding, but it does not provide an exact risk estimate for this antiplatelet medicine combination or demonstrate added stomach ulceration.
Consider the prescribed treatment
Ticagrelor reduces platelet activity and can cause serious bleeding. The label also warns that stopping it increases cardiovascular risk, including stent-related harm in relevant patients. Have your prescribing team review supplements and procedure plans; do not stop ticagrelor or assume that a few hours of spacing removes a possible bleeding concern.
Review the exact product
Bring the dose in mg or IU and formulation to your pharmacist. There is no validated vitamin E cutoff that guarantees safety with this drug. The high-dose supplement concern does not imply that vitamin E in ordinary foods must be avoided.
Know when to get help
Seek urgent care for bleeding that will not stop, vomiting blood or black, tarry stools. Tell your prescriber about the full supplement and medicine list. Do not stop prescribed antiplatelet treatment on your own to accommodate a supplement; ask the treating team to make a plan.
Evidence and practical considerations
Side effects & toxicity
An increased bleeding rate specifically from vitamin E supplements with ticagrelor has not been established.
- Exact scope
- Oral vitamin E supplements with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Available supplement-only and other-drug studies do not establish exact-pair clinical harm or exclude rare events. No validated preventive spacing interval.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral ticagrelor tablets users; short human pharmacology studies where described.
Significant bleeding risk; stopping treatment raises cardiovascular risk. Strong CYP3A inducers lower exposure and efficacy and should be avoided.
How this applies: Exact current product label. Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
No exact botanical bleeding rate. Rifampin exposure changes are not an effect size for St. John’s wort.
Source 2: Government nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Supplement users.
High doses may affect platelet/clotting function and increase bleeding concerns with anticoagulant or antiplatelet medicines.
How this applies: General supplement precaution with exact NSAID platelet and GI context.
No exact oral ticagrelor tablets trial or safe-dose cutoff; no demonstration of additive GI ulceration. Original guidance body read in captured web open.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
ticagrelor is IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Side effects & toxicity
High-dose vitamin E deserves individualized review with bleeding-risk medicines.
- Exact scope
- Oral vitamin E supplements with oral ticagrelor tablets. Exact formulation, dose and duration matter; other antiplatelet medicines and other supplement preparations are not interchangeable. with Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
- Medication form and route
- Oral
What remains uncertain
- Precaution based on defined supplement evidence and the individual drug label; no exact combination event rate or universal discontinuation rule.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral ticagrelor tablets users; short human pharmacology studies where described.
Significant bleeding risk; stopping treatment raises cardiovascular risk. Strong CYP3A inducers lower exposure and efficacy and should be avoided.
How this applies: Exact current product label. Exact ticagrelor RxCUI1116632 IN. Oral parent drug and active metabolite have antiplatelet activity; other P2Y12 drugs are not interchangeable.
No exact botanical bleeding rate. Rifampin exposure changes are not an effect size for St. John’s wort.
Source 2: Government nutrient guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Supplement users.
High doses may affect platelet/clotting function and increase bleeding concerns with anticoagulant or antiplatelet medicines.
How this applies: General supplement precaution with exact NSAID platelet and GI context.
No exact oral ticagrelor tablets trial or safe-dose cutoff; no demonstration of additive GI ulceration. Original guidance body read in captured web open.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: f03d990e5d134d16
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.